Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy

(2009) Martin R Tremblay et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

1-Amino-4-benzylphthalazines as Orally Bioavailable Smoothened Antagonists with Antitumor Activity

(2009) Karen Miller-Moslin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma

(2009) Paul A Northcott et al.   NATURE GENETICS

Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

(2009) Charles M. Rudin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

(2009) R. L. Yauch et al.   SCIENCE

Insulin-like Growth Factor 2Is Required for Progression to Advanced Medulloblastoma inpatched1Heterozygous Mice

(2008) Ryan B. Corcoran et al.   CANCER RESEARCH

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

(2008) Jeffrey A Engelman et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma

(2008) K. J. Briggs et al.   GENES & DEVELOPMENT

Hedgehog: functions and mechanisms

(2008) M. Varjosalo et al.   GENES & DEVELOPMENT

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

A paracrine requirement for hedgehog signalling in cancer

(2008) Robert L. Yauch et al.   NATURE

PTEN-deficient cancers depend on PIK3CB

(2008) S. Wee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA